SUPPLEMENTARY MATERIALS AND METHODS

Cell culture
Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Lonza) or RPMI (Lonza) supplemented with 10% FCS (Sigma). L-cells stably carrying an expression vector for mouse Wnt3a (L-Wnt3a cells) or its corresponding empty vector (L-Ctl cells) were cultured in the presence 0.4 mg/ml of geneticin (G418 disulfate, Fisher Scientific). Conditioned media from L-Ctl and L-Wnt3a cells was collected in the absence of geneticin and, where so denoted, added to cells during 48 h. Where indicated, cells were treated with Leptomycin-B (LMB) (Sigma, 10 ng/ml, 30 min), recombinant human Wnt3a (R&D Systems, 100 ng/ml for 24 h in the case of HCT116 cells or 48 h in SW480 cells) or amiloride (Sigma, 100 µM, 24 h).
Cell transfections
Cells were transfected with plasmids and siRNA oligonucleotides using Lipofectamine 2000 (Life Technologies) or, when exclusively transfected with siRNA oligonucleotides, using Lipofectamine RNAiMAX (Life Technologies) as described in (1) . After 48 h (by default, or at the time indicated in specific experiments), cells were processed for protein, mRNA or transcriptional analyses. SW480 cells were also stably infected with lentiviral particles encoding shRNAs (see below) followed by selection in puromycin (10 µg/ml)-containing media as described below. In some experiments, the resulting pooled stables were subsequently stably transfected with pCI-neo (CMV empty expression vector) (Promega Corp.) or pCI-neouPA (with the cDNA encoding human uPA) followed by selection in geneticin (0.7 mg/ml)-containing media.
Antibodies
Antibodies used in this article originated as follows: ZEB1 [H-102, E-20, and E-20-X from Santa Cruz Biotechnology (SCBT) and Zfhep as in (2) 
Plasmids
ZEB1 and ZEB1# NT expression vectors have been previously described (1) . Other expression vectors were obtained from the following researchers: !-catenin from J. Woodgett (Mount Sinai Hospital, Canada), uPA from GR Nemerow and S Huang (The Scripps Research Institute, La Jolla, CA) (3), CMV-p300-VP16AD from D Livingston (Dana Farber Cancer Institute, Boston, MA). Firefly luciferase reporters for the promoters tested here originated as follows: -1.94 kb of the human uPA from A Varro (University of Liverpool, Liverpool, UK) (4), -0.8 and -3.4 kb of human PAI-1 promoter from DE Vaughan (North Western University, Chicago) (5). pCI-neo was purchased from Promega, CMV-!-galactosidase from Clontech, and pBluescript SK from Stratagene-Agilent.
siRNAs and shRNAs
siRNAs were ordered from Invitrogen or Integrated DNA Technologies (IDT) using sequences reported elsewhere: two different siRNAs against human ZEB1 [siZEB1 as described in (6) (5'-UGAUCAGCCUCAAUC UGCA-3') and si2ZEB1 as in (7) (5'-AACUG AACCUGUGGAUUA-3')] and !-catenin (8) .
As negative control, we used a scramble control siRNA (5'-GGUUACGAACUAAGC UAUA-3') as well as (in Western blot/qRT-PCR studies) a siRNA against firefly luciferase as described in (9) . Lentiviral particles encoding shRNAs against human ZEB1, and whose target sequences are different from those in si1ZEB1 and si2ZEB1, consisted of a pool of three shRNAs (referred as shZEB1) (5'-GAAGCAG GAUGUACAGUAA-3', 5'-GGCGAUAGAUG GUAAUGUA-3', 5'-CCAGAACAGUGUUUA UUCU-3') were purchased from SCBT (sc-38643-V). Lentiviral particles for a control shRNA (also different from the siRNA control) were also obtained from SCBT (sc-108080-V).
Western Blot assays
Western blot assays were performed as previously described (1) . Briefly, cells were lysed in RIPA buffer (150 mM NaCl, 1% NP40, 0.5% SDS, 50 mM Tris pH 8, 2 mM EDTA plus protease inhibitors) and loaded onto 8% or 12% polyacrylamide gels. Gels were then transferred to a PVDF membrane (Immobilon-P, Millipore). Following blocking for nonspecific antibody binding with 5% nonfat milk, membranes were incubated with the corresponding primary and HRP-conjugated secondary antibodies before the reaction was developed using Pierce's ECL Western Blotting Substrate or SuperSignal West Pico Chemiluminescent Substrate (PierceThermo Fisher Scientific). Western blots shown in the article are representative of at least three independent experiments.
RNA Extraction and Quantitative Real-Time PCR
Total RNA extracted with Trizol reagent (MRC Inc.) followed by RNAse free DNAse I treatment (Promega) or SV Total RNA Isolation System (Promega) was used to synthesize cDNA with random hexamers/ oligodT with a reverse transcription kit (GoScript, Promega or iScript TM Reverse Transcription, BioRad) according to manufacturer's instructions. mRNA levels were determined by quantitative real-time PCR (qRT-PCR) at 60°C using either SYBR Green/ROX (GoTaq, Promega) or SYBR®Green (Biorad) and oligonucleotide primer sequences previously described in the literature: human ZEB1 (10), human E-cadherin (11), human uPA (12), human PAI-1 (13), human GAPDH (14), human !-actin (15), mouse uPA (16), mouse Id2 (17), mouse !-actin (18) or mouse GAPDH (19) . Relative mRNA levels were determined by Opticon Monitor 3.1.32 software (BioRad) by #Ct method normalizing values of genes under study to housekeeping GAPDH as reference gene. qRT-PCR data shown in the study are the average of at least three independent experiments performed in triplicate.
Site directed mutagenesis
Identification of ZEB1 consensus binding sequences was conducted using MacVector software. ZEB1 consensus binding sites at positions !1624 bp and !1480 bp in the human uPA promoter were mutated to sequences known to not bind ZEB1 using the QuickChange Lightning site-directed mutagenesis kit (Agilent) as per manufacturer's instructions. Complementary mutant primers to opposite strands of the target DNA were purchased from IDT. For the ZEB1 binding site at !1624 bp of human uPA promoter, the upper strand oligonucleotide sequence used is 5"-TCTCCA GAAGACAGTGGGTCTATTGCCTCCCAAA AGCTGAAAGGC-3'. For the ZEB1 binding site at !1480 bp of the human uPA promoter, the upper strand oligonucleotide sequence used is 5'-GCCTTCCTTCTGTCACTCTCTAATGGA CCCAGACCCAAGGTCCAG-3'. For the ZEB1 binding site at !230 bp of human uPA promoter, the upper strand oligonucleotide sequence used is 5"-CACTGGGGCAGGCCCCCGGCCTATT GCATGGGAGGAAGCACGGAG-3'. All three mutations were confirmed by sequencing with BigDye® Direct Cycle Sequencing Kit (Life Technologies-Applied Biosystems) with the followigng primers: 5"-TGGGAGTTTCGGGG TAAGTCCTC-3" 5'-TAACTTGTACTTTCCC CAGCAGGC-3', and 5'-GGTCTGAGGCAGT CTTAGGCAAGTTGG-3', respectively.
Transcriptional Assays
In transcriptional experiments, cells were transfected with firefly luciferase reporter vectors and equal molar amounts of either cDNA-containing or reference control empty expression vectors. As internal control for transfection efficiency, all points included cotransfection with 0.5 µg pCMV-!-gal. Total DNA was brought to the same amount by adding promoterless pBluescript SK vector. Firefly luciferase activity was assessed with a Luciferase Assay System kit (Promega Corp.), whereas !-galactosidase was determined with Luminiscent !-galactosidase Detection Kit II (Clontech). Relative luciferase activity values (RLU) throughout the article are expressed as the mean of duplicate and are representative of at least four independent experiments.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed using EpiQuick ChIP kit (Epigentek) as per manufacturer's instructions. Briefly, SW480 cells were incubated during 10 min with 1% formaldehyde solution (Electron Microscopy) at room temperature followed by incubation with 125 mM glycine. Lysates were sonicated as described (20) . Antibodies used for ChIP were as follows: goat anti-ZEB1 (E-20X) and normal goat IgG (JIR). DNA fragments were quantified by qRT-PCR as detailed above. Identification of DNA binding sequences for ZEB1 and design of primers for qRT-PCR was conducted using MacVector software. For the ZEB1 binding site at position -1624 bp of the human uPA promoter, the primers used were as follows: forward 5'-CAGCAAGCACAGAAGT CTCTCCAG-3' and reverse 5'-GAGTGACAG AAGGAAGGCAGGG-3'. For the ZEB1 binding site at position -1480 bp of the human uPA promoter, the primers used were as follows: forward 5'-TTCCTCCTTCCTACCTTCCTGG-3' and reverse 5'-TTCTGTCACGCCCATCTC TTTC-3'. For the ZEB1 binding site at position -230 bp of the human uPA promoter the primers used were as follows: forward 5'-GAAGAAC TGATTAGAGGACCC-3' and reverse 5'-ACA GCGTCTGGACTGAGG-3'.
For the amplification of a region of the uPA promoter with "no consensus binding sites" for ZEB1 (referred as NCBS in Figure 2D , -1376/-1223,) the following primers were used: forward 5'-TC CTCCTTCCCACTAAGAGAGC-3' and reverse 5'-CACACACACACACACGCATC-3'.Primers used for amplification of a fragment of the GAPDH promoter are included in the EpiQuick ChIP kit. In all qRT-PCRs, values shown represent relative binding in relation to input and are the average of three independent ChIP experiments, each in triplicate.
CRC cell migration and invasion assays
6.5 mm diameter/8 µm pore polycarbonate membrane Transwell TM inserts (Costar, Corning Inc.) were used directly for migration assays. For invasion assays, these Transwell inserts were first coated overnight with a 1/8 dilution of Matrigel TM matrix (BD Biosciences) in DMEM. Next, 1 x 10 5 cells in 100 µl of DMEM were added to Matrigel-Transwell inserts that were then placed on 24-well plates containing 650 µl of DMEM supplemented with 10% FCS. After incubation at 37°C during 6 h for migration or 24 h for invasion assays, cells on the upper surface of inserts were removed by washing with PBS and a cotton swab. Migration or invasive cells on the lower side of inserts were detached by incubation (30 min, 37°C) with Trypsin-EDTA, collected and counted by staining with Trypan blue. Results shown are the average of four independent experiments with triplicates of each condition, and cells counted thrice.
Immunohistochemistry and immunofluorescence analysis
Tissue samples were first immunostained by the horseradish peroxidase and 3, 3'-diaminobenzidine (DAB) method and, where indicated, processed for mutiple immunofluorescence analysis. Antigen retrieval was performed with 10 mM sodium citrate (pH 6.0). Slides for immuno-histochemistry were then treated with 0.3% H 2 O 2 in methanol to block endogenous peroxidase, whereas slides for immuno-fluorescence staining were first incubated for 30 min with 0.1% sodium borohydride. In either case, slides were next incubated with a non-specific binding blocking solution at 37°C (5% donkey normal serum, 4% BSA and 0.5% Tween 20 in PBS) followed by the corresponding primary (overnight at 4°C) and HRP-conjugated or fluorochromeconjugated secondary (1 h at 37 °C) antibodies. The immunohistochemistry reaction was developed with a DAB substrate Kit (Vector Labs) before slides were counterstained with hematoxylin and mounted in Di-NbutylPhthalate in Xylene solution (DPX, Sigma). The number of positively stained tumor cells in the CRC tissue array was scored by microscopic analysis at 400X magnification according to the following scale: 0 (0-10 positively stained cells), 1 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , 2 (21-30), 3 (31-40), 4 (41-50), 5 (over 50). Slides for immunofluorescence were mounted in Vectashield-DAPI (Vector Labs). Immunofluorescence was examined in a TCS SP5 Spectral confocal microscope (Leica) at the Microscopy Unit of the University of Barcelona, whose staff is here acknowledged for their technical advice. Images were analyzed using ImageJ software applying a median filter of 0.5-1 pixels. We are also grateful to E Jimenez for help in assembly of immunohistochemistry figures.
LEGENDS TO SUPPLEMENTARY FIGURES
Supplementary Figure S1 Upregulation of endogenous ZEB1 following nuclear translocation of !-catenin increases uPA and decreases PAI-1. Increase in ZEB1 mRNA levels in HCT116 cells in response to treatment with 10 ng/ml LMB for 30 min resulted in upregulated levels of uPA mRNA and decrease of PAI-1 mRNA. Cells were also subjected for 30 min to the same volume amount of the solvent in which LMB was resuspended (70% methanol, MeOH). Relative mRNA levels of uPA, PAI-1 and ZEB1 were determined by qRT-PCR respect to GAPDH. (G) Upregulation of endogenous ZEB1 following activation of Wnt signaling increases uPA and decreases PAI-1. HTC116 cells were either untreated (Unt) or exposed during 24 h to 100 ng/ml of recombinant human Wnt3a. Relative mRNA levels of uPA, PAI-1 and ZEB1 were determined by qRT-PCR respect to GAPDH. 
Supplementary Figure S2
Supplementary Figure S3
ZEB1 expression decreases PAI-1 mRNA stability. SW480 cells stably transfected with a shRNA control (shCtl) or against ZEB1 (sh1ZEB1) were incubated for the indicated periods with 10 µg/ml of Actinomycin D (Act D) before relative mRNA levels of PAI-1 were analyzed by qRT-PCR respect to GAPDH as reference gene.
Supplementary Figure S4
The uPA inhibitor amiloride blocks ZEB1-mediated invasiveness. (A) SW480 stable cell lines described in Figure 4A were tested for their ability to invade through a Matrigel matrix during 24 h in the presence of either 100 µM of amiloride or equal volume of its solvent (DMSO). Invasion assays were performed as described in Materials and Methods. A t-test for significance of means difference was used. (B) Amiloride reduces uPA expression in SW480 cells. SW480 cells were treated for 24 h with either 100 µM of amiloride or equal volume of DMSO. Cells lysates were assessed by Western blot for expression of ZEB1 (H-102) and uPA (3689/HD-UK1) proteins using "-tubulin (B5-1-2) as loading control.
Supplementary Figure S5
(A) Expression of ZEB1 in the developing intestine. As in Figure 5A , immunohistochemistry for ZEB1 (Zfhep Ab) in the intestine of ZEB1 wild type (+/+) and null (-/-) E18.5 mouse embryos. (B) Single staining for uPA (blue, 3689/HD-UK1), ZEB1 (red, E-20) and !-catenin (green, Ab6302) corresponding to tumor front pictures in Figure 5D . uPA was originally detected with Dylight 649 (invisible far red) but converted to blue for representation. DAPI staining is also shown. Scale bars represent 25 µm. (C) As in (B) but corresponding to tumor center pictures in Figure  5D . (D) ZEB1 colocalizes with uPA in invading cancer cells at the tumor front of CRCs. As in Figure 5D but for an alternative (more differentiated area) of the tumor front. (E) As in (B), single staining for uPA, ZEB1 and !-catenin corresponding to tumor front pictures in panel (D).
